CTOs on the Move


 
Akouos is a precision genetic medicine company dedicated to developing gene therapies that restore and preserve hearing. Leveraging its adeno-associated viral (AAV) vector-based gene therapy platform, Akouos is focused on developing precision therapies for forms of sensorineural hearing loss. Headquartered in Boston, the Company was founded in 2016 by world leaders in the fields of neurotology, genetics, inner ear drug delivery, and AAV gene therapy. Akouos has strategic partnerships with Massachusetts Eye and Ear Infirmary and Lonza, Inc
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.akouos.com
  • 645 Summer Street Suite 200
    Boston, MA USA 02210
  • Phone: n/a

Executives

Name Title Contact Details
Stacy Price
Chief Technical Officer Profile
Alan Smith
Chief Technology Officer Profile
Alan Smith
Chief Technology Officer Profile

Funding

Akouos raised $105M on 03/03/2020

Similar Companies

Agenta Biotechnologies

Agenta Biotechnologies is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Future Family

Future Family is where women, men and couples start their fertility journey. The company`s mission is to make fertility care accessible and affordable to all.

Bionest Partners

Bionest Partners is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

G1 Therapeutics

G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the treatment of cancer. Two of the company`s pipeline assets, trilaciclib and G1T38, are CDK4/6 inhibitors, a validated and promising class of oncology therapeutics. Trilaciclib and G1T38 have broad therapeutic potential in many forms of cancer and may serve as backbone therapy of multiple combination regimens. Trilaciclib is a short-acting IV CDK4/6 inhibitor designed to preserve hematopoietic stem cell and immune system function (myelopreservation) during chemotherapy. G1T38 is a potential best-in-class oral CDK4/6 inhibitor for use in combination with other targeted therapies. G1 is also advancing G1T48, a potential best-in-class oral selective estrogen receptor degrader, or SERD, which is targeted for the treatment of ER+ breast cancer.

Indevus Pharmaceuticals

Indevus Pharmaceuticals Inc. is a Lexington, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.